SNDX Q4 2021 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$127M+33209.5% YoY

Gross Profit

$126M99.9% margin

Operating Income

$96M75.6% margin

Net Income

$96M76.0% margin

EPS (Diluted)

$1.81

QoQ Revenue Growth

+922.8%

Cash Flow

Operating Cash Flow

$101M

Free Cash Flow

$101M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$450M

Total Liabilities

$41M

Stockholders' Equity

$408M

Cash & Equivalents

$222M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$127M	$380,000	+33209.5%
Gross Profit	$126M	$379,000	+33265.4%
Operating Income	$96M	-$20M	+582.1%
Net Income	$96M	-$20M	+571.0%